Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...

Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following announcements that pharmaceutical giant Pfizer Inc. (NYSE:PFE) terminated ...

Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...

Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...

In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...

Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, terminated its global collaboration and license agreement for giroctocogene ...

Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following announcements that pharmaceutical giant Pfizer Inc. (NYSE:PFE) terminated ...